PPT-Tenofovir

based PrEP technologies in women what do we currently know LindaGail Bekker The Desmond Tutu HIV Centre University of Cape Town Expanding HIV Prevention Options for Women The need for a female initiated managed and controlled prevention methodology. GeneProteinMechanismTissuedistributionlocalizationExamplesofdrugsubstratesReferences OAT1DC/OAKidneyBLMAdefovir,cidofovir,acyclovir,didanosine,stavudine,triuridine,ganciclovir,PMEG,PMEDAP,tenofovir,z of the evidence from oral and topical . PrEP. efficacy . trials. What . we know and what we still need to . know.. Javier R. Lama, MD, MPH. Director. , HIV Prevention Intervention Studies. IMPACTA PERU Clinical Trials . An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. Jennifer Hoy. , MBBS. Professor of Medicine. Director, HIV Medicine. The Alfred Hospital. FINAL: 07-20-12. Phillip, Aged 67 Years. HIV infection diagnosed on screening for HBV treatment trial in 1995. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm. M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, Frontier AETC ECHO. October 2015. ID Week Review 2015. 1) Switching from TDF to TAF. 2) Simplifying salvage therapy to E/C/F/TAF + DRV. Lessons Learned from Tenofovir Vaginal Gel Studies. Salim S. Abdool Karim. Director: CAPRISA. CAPRISA Professor of Global Health, Columbia University. Pro Vice-Chancellor (Research): University of KwaZulu-Natal. Efficacy and the importance of adherence. Joanne . Stekler. , MD MPH. August 20, 2015. Key HIV . PrEP. Trials Using Oral . Tenofovir. (TDF) or . Tenofovir-Emtricitabine. (TDF-FTC). Study. Study Population. Access and Rational Use. Blood, Radiological and Pharmaceutical Services. Regulatory System Strengthening. Systems approach/ Across all technologies. Contemplate the specificities off specific technologies. Drew Lambert, . PharmD. lambertd@husson.edu. Husson University School of Pharmacy. 1. PollEverywhere. - Text . DREWLAMBERT221 to 22333 to join. You . can respond at . PollEv.com/drewlambert221. I have no conflicts of interest.. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg.